Skip to content
Austin Top 50
Author:
FibroBiologics, Inc.
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial
March 31, 2026
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
March 25, 2026
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
March 12, 2026
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
March 5, 2026
←
Previous Page
1
2
3